BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-71@pharmaconomics
DTSTAMP:20260707T003324Z
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261021
SUMMARY:BIIB Phase 3 — Litifilimab
DESCRIPTION:Phase 3 trial results for Litifilimab in Subacute Cutaneous Lupus Erythematosus are due Oct 20\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/exhibit991-q42025pressrele.htm\n\nTrack it: https://pharmaconomics.com/e/71
URL:https://pharmaconomics.com/e/71
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BIIB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR